A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL

NCT04361279 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

421

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG: SIBP-02
DRUG: Rituximab

Sponsor

Shanghai Institute Of Biological Products